The efficacy of EGFR-TKIs has been confirmed and they are approved as a first-line treatment for NSCLC.[14] A subtype analysis showed that EGFR mutations were more pronounced in Asians, females, non-smokers, and patients with adenocarcinoma of the lungs.[15] The patient reported on here belongs to the high-risk EGFR mutation group. This evidence concerns the gene EGFR and non-small cell lung carcinoma.